These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 9566469)

  • 1. Power and sample size calculations for stochastic cost-effectiveness analysis.
    Briggs AH; Gray AM
    Med Decis Making; 1998; 18(2 Suppl):S81-92. PubMed ID: 9566469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data.
    Willan AR; O'Brien BJ
    Health Econ; 1999 May; 8(3):203-11. PubMed ID: 10348415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of randomised controlled trials for producing cost-effectiveness evidence: potential impact of design choices on sample size and study duration.
    Backhouse ME
    Pharmacoeconomics; 2002; 20(15):1061-77. PubMed ID: 12456201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies.
    Briggs AH; O'Brien BJ; Blackhouse G
    Annu Rev Public Health; 2002; 23():377-401. PubMed ID: 11910068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A C++ program to calculate sample sizes for cost-effectiveness trials in a Bayesian framework.
    Sarker SJ; Whitehead A; Khan I
    Comput Methods Programs Biomed; 2013 Jun; 110(3):471-89. PubMed ID: 23399102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem.
    Willan AR; O'Brien BJ
    Health Econ; 1996; 5(4):297-305. PubMed ID: 8880166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and analysis issues for economic analysis alongside clinical trials.
    Marshall DA; Hux M
    Med Care; 2009 Jul; 47(7 Suppl 1):S14-20. PubMed ID: 19536012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An opportunity cost approach to sample size calculation in cost-effectiveness analysis.
    Gafni A; Walter SD; Birch S; Sendi P
    Health Econ; 2008 Jan; 17(1):99-107. PubMed ID: 17497751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian assessment of sample size for clinical trials of cost-effectiveness.
    O'Hagan A; Stevens JW
    Med Decis Making; 2001; 21(3):219-30. PubMed ID: 11386629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation, power and sample size calculations for stochastic cost and effectiveness analysis.
    Walter SD; Gafni A; Birch S
    Pharmacoeconomics; 2007; 25(6):455-66. PubMed ID: 17523751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design issues for conducting cost-effectiveness analyses alongside clinical trials.
    Ramsey SD; McIntosh M; Sullivan SD
    Annu Rev Public Health; 2001; 22():129-41. PubMed ID: 11274515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Conducting a cost-effectiveness trial in oncology: justification and method].
    Lejeune C; Binquet C; Bonnetain F
    Bull Cancer; 2009 May; 96(5):603-7. PubMed ID: 19435689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic endpoints in clinical trials.
    Cook J; Drummond M; Heyse JF
    Stat Methods Med Res; 2004 Apr; 13(2):157-76. PubMed ID: 15068259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of confidence intervals and sample size calculations in health economic studies.
    Sacristán JA; Day SJ; Navarro O; Ramos J; Hernández JM
    Ann Pharmacother; 1995; 29(7-8):719-25. PubMed ID: 8520090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new approach for sample size calculation in cost-effectiveness studies based on value of information.
    Bader C; Cossin S; Maillard A; Bénard A
    BMC Med Res Methodol; 2018 Oct; 18(1):113. PubMed ID: 30348087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Power and sample size calculation for incremental net benefit in cost effectiveness analyses with applications to trials conducted by the Canadian Cancer Trials Group.
    Everest L; Chen BE; Hay AE; Cheung MC; Chan KKW
    BMC Med Res Methodol; 2023 Aug; 23(1):179. PubMed ID: 37537545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
    Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
    Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bootstrapping: estimating confidence intervals for cost-effectiveness ratios.
    Campbell MK; Torgerson DJ
    QJM; 1999 Mar; 92(3):177-82. PubMed ID: 10326078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Power and sample size for cost-effectiveness analysis: fFN neonatal screening.
    Boyd KA; Briggs AH; Fenwick E; Norrie J; Stock S
    Contemp Clin Trials; 2011 Nov; 32(6):893-901. PubMed ID: 21782976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal and maximin sample sizes for multicentre cost-effectiveness trials.
    Manju MA; Candel MJ; Berger MP
    Stat Methods Med Res; 2015 Oct; 24(5):513-39. PubMed ID: 25656551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.